• +1-646-491-9876
    • +91-20-67278686

    Search

    Primary Biliary Cirrhosis - Pipeline Review, H1 2017

    Primary Biliary Cirrhosis - Pipeline Review, H1 2017

    • Report Code ID: RW0001689398
    • Category Healthcare
    • No. of Pages 95
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2017, provides an overview of the Primary Biliary Cirrhosis (Gastrointestinal) pipeline landscape.

    Primary biliary cirrhosis is a chronic disease of the liver that slowly destroys the bile ducts within the liver. Symptoms include fatigue, itchy skin, dry eyes, jaundice, swollen feet and ankles, pain in the upper right portion of the abdomen and diarrhea. Predisposing factors include age and history of infections. Treatment includes bile acid sequestrants and liver transplantation.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Primary Biliary Cirrhosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Primary Biliary Cirrhosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Phase 0 stages are 1, 1, 9, 5 and 1 respectively.

    Primary Biliary Cirrhosis (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Primary Biliary Cirrhosis (Gastrointestinal).
    - The pipeline guide reviews pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Primary Biliary Cirrhosis (Gastrointestinal) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Primary Biliary Cirrhosis (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Primary Biliary Cirrhosis (Gastrointestinal)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Primary Biliary Cirrhosis (Gastrointestinal).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Primary Biliary Cirrhosis (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Primary Biliary Cirrhosis - Overview
    Primary Biliary Cirrhosis - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Primary Biliary Cirrhosis - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Primary Biliary Cirrhosis - Companies Involved in Therapeutics Development
    Albireo Pharma Inc
    Arena Pharmaceuticals Inc
    CymaBay Therapeutics Inc
    Eisai Co Ltd
    Enanta Pharmaceuticals Inc
    Genextra Spa
    Genfit SA
    GenKyoTex SA
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    MediGene AG
    NGM Biopharmaceuticals Inc
    Novartis AG
    Retrophin Inc
    Shire Plc
    Virobay Inc
    Primary Biliary Cirrhosis - Drug Profiles
    A-4250 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    E-6011 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    EDP-305 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    elafibranor - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    etrasimod arginine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    FFP-104 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GKT-831 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GS-9674 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GSK-2330672 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LJN-452 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    maralixibat chloride - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NGM-282 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    obeticholic acid - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    RhuDex - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    seladelpar - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ursodiol - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VBY-825 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Primary Biliary Cirrhosis - Dormant Projects
    Primary Biliary Cirrhosis - Product Development Milestones
    Featured News & Press Releases
    Nov 04, 2016: GENFIT: FDA has officially cleared the IND to proceed with Phase II trial and evaluate elafibranor in PBC
    Oct 20, 2016: CymaBay Therapeutics Announces an Oral Late-Breaking Presentation of a Phase 2 Proof-of-Concept Study of MBX-8025 in Patients With Primary Biliary Cholangitis at the AASLD 2016 Liver Meeting
    Oct 20, 2016: CymaBay Therapeutics Announces that MBX-8025 has Received European Medicines Agency PRIority MEdicines Designation for the Treatment of Primary Biliary Cholangitis
    Oct 05, 2016: CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis
    Aug 17, 2016: New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC
    May 31, 2016: CymaBay Therapeutics Announces Top Line Efficacy and Safety Data From Its Phase 2 Study of Mbx-8025 in Patients With Primary Biliary Cholangitis (PBC)
    May 27, 2016: FDA Grants Accelerated Approval to Ocaliva (Obeticholic Acid) for the Treatment of Patients with PBC
    May 18, 2016: Intercept Announces Ocaliva (Obeticholic Acid) Data in PBC to be Presented at DDW 2016
    Apr 14, 2016: New Analyses of the Phase 3 POISE Trial of Ocaliva (Obeticholic Acid) for the Treatment of PBC Presented at EASL
    Apr 07, 2016: FDA Advisory Committee Unanimously Recommends Accelerated Approval of Ocaliva (obeticholic acid) for the Treatment of PBC
    Mar 30, 2016: Intercept Announces New OCA Data in PBC and NASH to be Presented at EASL 2016
    Feb 03, 2016: Fast Forward Pharmaceuticals Initiates Phase II Pilot Studies in Primary Biliary Cirrhosis and Crohn’s Disease with anti-CD40 Monoclonal Antibody
    Dec 17, 2015: FDA Extends PDUFA Date for Obeticholic Acid for the Treatment of PBC
    Nov 14, 2015: Intercept Presents New PBC Data at AASLD 2015
    Nov 10, 2015: CymaBay Therapeutics Announces the Initiation of a Phase 2 Study of MBX-8025 in Patients With Primary Biliary Cholangitis/Cirrhosis
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Primary Biliary Cirrhosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Albireo Pharma Inc, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Arena Pharmaceuticals Inc, H1 2017
    Primary Biliary Cirrhosis - Pipeline by CymaBay Therapeutics Inc, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Eisai Co Ltd, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Enanta Pharmaceuticals Inc, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Genextra Spa, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Genfit SA, H1 2017
    Primary Biliary Cirrhosis - Pipeline by GenKyoTex SA, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Gilead Sciences Inc, H1 2017
    Primary Biliary Cirrhosis - Pipeline by GlaxoSmithKline Plc, H1 2017
    Primary Biliary Cirrhosis - Pipeline by MediGene AG, H1 2017
    Primary Biliary Cirrhosis - Pipeline by NGM Biopharmaceuticals Inc, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Novartis AG, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Retrophin Inc, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Shire Plc, H1 2017
    Primary Biliary Cirrhosis - Pipeline by Virobay Inc, H1 2017
    Primary Biliary Cirrhosis - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Primary Biliary Cirrhosis, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Albireo Pharma Inc
    Arena Pharmaceuticals Inc
    CymaBay Therapeutics Inc
    Eisai Co Ltd
    Enanta Pharmaceuticals Inc
    Genextra Spa
    Genfit SA
    GenKyoTex SA
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    MediGene AG
    NGM Biopharmaceuticals Inc
    Novartis AG
    Retrophin Inc
    Shire Plc
    Virobay Inc

    Request for Sample

    Report Url https://www.reportsweb.com//primary-biliary-cirrhosis-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//primary-biliary-cirrhosis-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//primary-biliary-cirrhosis-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments